retatrutide mechanism triple agonist glp-1 gip glucagon ly3437943 A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology Simple Peptide retatrutide: complete guide

Nasr NE, Sadek KM

You wont find it in prescribing information or clinical guidelines

Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA

doi: 10.1016/j.regpep.2008.07.003

However, these studies are observational, not randomized trials, so we cannot yet interpret the findings as proof of a cancer risk reduction. The review also addressed the question of whether GLP-1s reduce cancer risk because they cause weight loss and improved metabolism, or because they have a direct anti-cancer effect

Case 2: Due to a national shortage of 1.0 mg semaglutide, a female whose weight was previously stable on phentermine 15mg/topiramate 25mg twice daily plus GLP-1 agonist therapy (i.e., semaglutide) was switched to 5mg tirzepatide in-between clinic visits